Developer docs
API playgroundTry for free, no card

Search company profiles

Diopsys

Full company profile

uuid0004ai4

Namestring
Diopsys
Websiteurl
diopsys.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Diopsys is a privately held medical device company founded in 1998 and headquartered in Pine Brook, New Jersey, that develops electroretinography (ERG) and visual evoked potential (VEP) vision-testing equipment for clinical diagnostic use. Its products are sold to healthcare providers — primarily ophthalmology and optometry practices — to objectively assess retinal and visual pathway function in patients, including those covered by Medicare and Medicaid.

The company operates with a small employee base of 11-50 people and distributes its devices through medical-device sales channels to healthcare providers. Its customer base is concentrated in clinical practices billing government healthcare programs, making federal reimbursement a critical component of its revenue model. Pricing, contract structures, and direct distribution details are not publicly disclosed.

Diopsys has been the subject of significant regulatory enforcement action. According to the available data, in March 2026 the company agreed to a $14.25 million settlement with the U.S. Department of Justice for allegedly causing providers to bill Medicare and Medicaid for medically unnecessary vision tests using an uncleared device. The settlement is the single most material documented event in the company's history and frames any investment assessment around regulatory risk tied to device clearance and federal program billing compliance.

Short descriptiontext

Diopsys is a privately held medical device company founded in 1998, headquartered in Pine Brook, NJ, that develops ERG and VEP vision-testing equipment for healthcare providers, including those serving Medicare and Medicaid patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMiddletown, United States
HQ citystring
Middletown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
medical diagnostic devices, vision testing equipment, electroretinography devices, visual evoked potential systems, ophthalmic diagnostic equipment
Industry2 codes
PRIMARYHLAHAJAC
Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAA
Comprehensive Eye Exams & Vision Care
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Ophthalmic Diagnostic Devices
Social media profiles3 records
Cost components5 values
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Diopsys designs, manufactures, and sells medical devices used by healthcare providers to perform electroretinography (ERG) and visual evoked potential (VEP) vision tests for diagnostic purposes. The company's products are deployed in clinical settings to support patient diagnosis of vision disorders.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Diopsys offers vision testing devices/equipment. Based on enforcement-related news sources, Diopsys produces medical devices used for vision testing, with its devices being the subject of a DOJ settlement related to Medicare and Medicaid billing for vision tests.

Product and service2 records
1ERG (Electroretinography) Vision Testing Device
CategoryOphthalmic Diagnostic Devices
Description

Medical device used by healthcare providers to perform electroretinography vision tests for diagnostic evaluation of retinal function in patients.

2VEP (Visual Evoked Potential) Vision Testing Device
CategoryOphthalmic Diagnostic Devices
Description

Medical device used by healthcare providers to perform visual evoked potential tests for diagnostic evaluation of the visual pathway in patients.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeDirect peer
Description

LKC Technologies produces electrophysiology devices including ERG and visual testing equipment, and is one of the closest functional peers to Diopsys in vision electrophysiology instrumentation.

TypeEmerging player
Description

Konan Medical specializes in objective functional vision testing (e.g., pupillometry and perimetry), making it a relevant emerging/specialty peer adjacent to Diopsys' electrophysiology focus.

TypeBroad incumbent
Description

Haag-Streit offers ophthalmic diagnostic equipment and perimetry systems used in the same clinical vision-testing environments as Diopsys' ERG/VEP products.

TypeBroad incumbent
Description

Heidelberg Engineering is an established ophthalmic diagnostic imaging and spectroscopy platform company whose portfolio overlaps with Diopsys' clinical vision diagnostics customers and sales channels.

TypeEmerging player
Description

Natus Medical manufactures neurodiagnostic and electrophysiology equipment used in vision and neurology testing, providing adjacent peer comparison on ERG/VEP underlying technology.

6Carl Zeiss Meditec
TypeBroad incumbent
Description

Carl Zeiss Meditec offers a broad portfolio of ophthalmic diagnostic and surgical equipment, including imaging and functional testing, competing in the same provider purchasing workflows as Diopsys.

TypeBroad incumbent
Description

Topcon Healthcare markets ophthalmic and optometric diagnostic instruments, including imaging and functional testing devices, sharing Diopsys' optometry and ophthalmology end-user base.

TypeBroad incumbent
Description

Nidek manufactures a broad range of ophthalmic diagnostic devices and shares significant overlap with Diopsys in eye-care provider equipment sales channels.

TypeBroad incumbent
Description

Reichert Technologies manufactures ophthalmic diagnostic instruments including tonometers and refractors, sharing the same vision-care provider channel as Diopsys.

TypeDirect peer
Description

Diagnosys designs and manufactures clinical electroretinography (ERG) and visual evoked potential (VEP) systems, directly competing with Diopsys in the electrophysiology-based ophthalmic diagnostic segment.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Diopsys

Ophthalmic Diagnostic Devicesdiopsys.com

Diopsys is a privately held medical device company founded in 1998, headquartered in Pine Brook, NJ, that develops ERG and VEP vision-testing equipment for healthcare providers, including those serving Medicare and Medicaid patients.

What Diopsys does

Diopsys is a privately held medical device company founded in 1998 and headquartered in Pine Brook, New Jersey, that develops electroretinography (ERG) and visual evoked potential (VEP) vision-testing equipment for clinical diagnostic use. Its products are sold to healthcare providers — primarily ophthalmology and optometry practices — to objectively assess retinal and visual pathway function in patients, including those covered by Medicare and Medicaid.

The company operates with a small employee base of 11-50 people and distributes its devices through medical-device sales channels to healthcare providers. Its customer base is concentrated in clinical practices billing government healthcare programs, making federal reimbursement a critical component of its revenue model. Pricing, contract structures, and direct distribution details are not publicly disclosed.

Diopsys has been the subject of significant regulatory enforcement action. According to the available data, in March 2026 the company agreed to a $14.25 million settlement with the U.S. Department of Justice for allegedly causing providers to bill Medicare and Medicaid for medically unnecessary vision tests using an uncleared device. The settlement is the single most material documented event in the company's history and frames any investment assessment around regulatory risk tied to device clearance and federal program billing compliance.

Diopsys firmographics

Firmographics
Name
Diopsys
Website
https://diopsys.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
11–50 employees
Short description
Diopsys is a privately held medical device company founded in 1998, headquartered in Pine Brook, NJ, that develops ERG and VEP vision-testing equipment for healthcare providers, including those serving Medicare and Medicaid patients.
Ownership category
akta.pro rank

Diopsys industry classification

Industry
Product category
Ophthalmic Diagnostic Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAJAC
Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAA
Comprehensive Eye Exams & Vision Care

Keywords

  • Medical diagnostic devices
  • Vision testing equipment
  • Electroretinography devices
  • Visual evoked potential systems
  • Ophthalmic diagnostic equipment

Where Diopsys is headquartered

Location

Headquarters

HQ city
Middletown
HQ country
United States
HQ region
North America

Markets served

Diopsys business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Diopsys product offering

Product offering

Core offering

Diopsys designs, manufactures, and sells medical devices used by healthcare providers to perform electroretinography (ERG) and visual evoked potential (VEP) vision tests for diagnostic purposes. The company's products are deployed in clinical settings to support patient diagnosis of vision disorders.

Product overview

Diopsys offers vision testing devices/equipment. Based on enforcement-related news sources, Diopsys produces medical devices used for vision testing, with its devices being the subject of a DOJ settlement related to Medicare and Medicaid billing for vision tests.

Differentiator

Problem solved

Functional benefit

Products and services

  • ERG (Electroretinography) Vision Testing Device Medical device used by healthcare providers to perform electroretinography vision tests for diagnostic evaluation of retinal function in patients.
  • VEP (Visual Evoked Potential) Vision Testing Device Medical device used by healthcare providers to perform visual evoked potential tests for diagnostic evaluation of the visual pathway in patients.

Companies that use Diopsys

Customer profile

Segments2 records

Ideal customer profiles2 records

Diopsys technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Diopsys partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves3 records

Diopsys competitors and assessment

Company assessment

Direct peers

  • LKC Technologies: LKC Technologies produces electrophysiology devices including ERG and visual testing equipment, and is one of the closest functional peers to Diopsys in vision electrophysiology instrumentation.
  • Diagnosys LLC: Diagnosys designs and manufactures clinical electroretinography (ERG) and visual evoked potential (VEP) systems, directly competing with Diopsys in the electrophysiology-based ophthalmic diagnostic segment.

Emerging players

  • Konan Medical: Konan Medical specializes in objective functional vision testing (e.g., pupillometry and perimetry), making it a relevant emerging/specialty peer adjacent to Diopsys' electrophysiology focus.
  • Natus Medical Incorporated: Natus Medical manufactures neurodiagnostic and electrophysiology equipment used in vision and neurology testing, providing adjacent peer comparison on ERG/VEP underlying technology.

Broad incumbents

  • Haag-Streit Group: Haag-Streit offers ophthalmic diagnostic equipment and perimetry systems used in the same clinical vision-testing environments as Diopsys' ERG/VEP products.
  • Heidelberg Engineering: Heidelberg Engineering is an established ophthalmic diagnostic imaging and spectroscopy platform company whose portfolio overlaps with Diopsys' clinical vision diagnostics customers and sales channels.
  • Carl Zeiss Meditec: Carl Zeiss Meditec offers a broad portfolio of ophthalmic diagnostic and surgical equipment, including imaging and functional testing, competing in the same provider purchasing workflows as Diopsys.
  • Topcon Healthcare: Topcon Healthcare markets ophthalmic and optometric diagnostic instruments, including imaging and functional testing devices, sharing Diopsys' optometry and ophthalmology end-user base.
  • Nidek Co., Ltd. Nidek manufactures a broad range of ophthalmic diagnostic devices and shares significant overlap with Diopsys in eye-care provider equipment sales channels.
  • Reichert Technologies (AMETEK): Reichert Technologies manufactures ophthalmic diagnostic instruments including tonometers and refractors, sharing the same vision-care provider channel as Diopsys.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights3 records

Customer concentration

Diopsys social profiles

Digital presence

Diopsys financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Diopsys leadership team

Management profile

Number of profiles

Profiles1 record

Diopsys funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Diopsys M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diopsys

What does Diopsys do?

Diopsys designs, manufactures, and sells medical devices used by healthcare providers to perform electroretinography (ERG) and visual evoked potential (VEP) vision tests for diagnostic purposes. The company's products are deployed in clinical settings to support patient diagnosis of vision disorders.

Is Diopsys a public or private company?

Diopsys is a private company. It is classified as unknown and is currently operating.

When was Diopsys founded?

Diopsys was founded in 1998. It employs 11 to 50 people.

Where is Diopsys based?

Diopsys is headquartered in Middletown, United States, in the North America region.

Who are Diopsys's main competitors?

Direct peers on record are LKC Technologies and Diagnosys LLC. Emerging players are Konan Medical and Natus Medical Incorporated. Broad incumbents are Haag-Streit Group, Heidelberg Engineering, Carl Zeiss Meditec, Topcon Healthcare, Nidek Co., Ltd. and Reichert Technologies (AMETEK).

Does Diopsys have an API?

No public API is recorded for Diopsys.

What industry is Diopsys in?

Diopsys's product category is Ophthalmic Diagnostic Devices. Its primary akta.pro industry code is HLAHAJAC, Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity), with a secondary code of HLAKAKAA, Comprehensive Eye Exams & Vision Care. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Bloomberg Law NewsWhat Medical Device Companies Need to Know About DOJ EnforcementThe Department of Justice is intensifying enforcement against medical device companies, with False Claims Act recoveries totaling $6.8 billion in fiscal year 2025, of which over 83% involved health-care matters, and more than one-third coming from qui tam relators litigating independently. Recent enforcement actions include ExThera Medical's $750,000 deferred prosecution agreement for failing to file adverse event reports related to a blood filtration device, Aesculap's $38.5 million settlement for selling defective knee replacement devices and paying kickbacks to surgeons, and Diopsys's $14.25 million settlement for causing providers to bill Medicare and Medicaid for medically unnecessary vision tests using an uncleared device. The July 2025 renewal of the DOJ-HHS FCA Working Group signals continued heightened scrutiny focused on kickbacks, materially defective devices affecting patient safety, and drug and device pricing.PR NewswireDiopsys, Inc. gibt Umzug an erweiterten Hauptsitz in New Jersey bekanntDiopsys, Inc., a 100% subsidiary of LumiThera, Inc., has relocated to an expanded 17,000 square foot headquarters in Cedar Knolls, New Jersey, three months after being acquired by LumiThera to provide complementary diagnostic capabilities for LumiThera's Valeda Light Delivery System. The new East Coast facility will accommodate expanded operations, research and development labs, warehousing, and manufacturing capacity to support worldwide expansion of their combined theranostic platforms. LumiThera also announced statistically significant 13-month LIGHTSITE-III clinical trial results showing sustained vision improvement in dry age-related macular degeneration patients treated with Valeda, supporting their pending FDA PMA application.PR NewswireDiopsys, Inc. anuncia el traslado a una sede ampliada en Nueva JerseyDiopsys, Inc., a leader in visual electrophysiology medical devices, announced its move to expanded facilities in Cedar Knolls, New Jersey, following its acquisition as a wholly-owned subsidiary of LumiThera, Inc. three months prior; the new 17,000 square foot facility will house operations, R&D labs, warehousing, and manufacturing capabilities. LumiThera also reported positive LIGHTSITE III clinical trial results showing statistically significant vision improvements in patients with intermediate dry age-related macular degeneration treated with the Valeda Light Delivery System. The combined teranostic platform aims to provide eye care professionals with diagnostic, treatment, and monitoring tools for degenerative eye diseases with limited treatment options.PR NewswireDiopsys, Inc. annonce le déménagement vers son siège social agrandi dans le New JerseyDiopsys, Inc. is relocating to an expanded headquarters in Cedar Knolls, New Jersey, three months after becoming a wholly-owned subsidiary of LumiThera, Inc. The new 1,580 square meter facility will accommodate operations, R&D labs, warehouse, and manufacturing capabilities to support the combined company's global expansion of its theranostic platforms for eye disease diagnosis and treatment. LumiThera is simultaneously pursuing FDA approval for its Valeda Light Delivery System following positive 13-month LIGHTSITE III trial results showing statistically significant vision improvement in dry age-related macular degeneration patients.PR NewswireDiopsys, Inc. Announces Move to Expanded Headquarters in New JerseyDiopsys, Inc. has relocated its headquarters to a new 17,000 square foot facility in Cedar Knolls, New Jersey, following its acquisition by LumiThera, Inc. three months prior. This move establishes an east coast operations center intended to support global expansion and combine Diopsys' U.S. sales force with LumiThera's EU team. The relocation supports the development of theranostic platforms for ocular diseases while LumiThera prepares a PMA submission to the FDA based on positive LIGHTSITE III trial data.PR NewswireDiopsys, Inc. Annuncia il trasferimento nella sede ampliata nel New JerseyDiopsys, Inc., a leader in visual electrophysiology medical devices, has relocated to an expanded headquarters in Cedar Knolls, New Jersey, three months after becoming a wholly-owned subsidiary of LumiThera, Inc. The new 16,000 square meter facility provides space for operational and R&D laboratories, warehouse, and production capabilities, combining Diopsys' US commercial sales force with LumiThera's EU team to serve a global ophthalmology audience. LumiThera also announced positive 13-month results from its LIGHTSITE III US study showing statistically significant improvement in best-corrected visual acuity for patients with intermediate dry age-related macular degeneration treated with the Valeda Light Delivery System.FierceBiotechDry AMD treatment developer LumiThera nets retinal diagnostic maker DiopsysLumiThera acquired Diopsys, a maker of retinal diagnostic equipment, to complement its dry AMD treatment. The company plans to use Diopsys' Nova system to monitor patient responses in a sham-controlled trial expected to begin collecting data early this year. Financial terms were not disclosed.PR NewswireLumiThera, Inc. annonce la finalisation de l'acquisition de Diopsys, Inc.LumiThera Inc. has completed the acquisition of Diopsys, Inc., a pioneer in modern visual electrophysiology medical devices, making Diopsys a wholly-owned subsidiary. The acquisition integrates Diopsys's established U.S. sales force and diagnostic technology — including ERG and VEP testing devices — with LumiThera's Valeda Light Delivery System, creating a combined diagnostic, treatment, and monitoring platform for ophthalmic diseases. The announcement comes ahead of potential 13-month efficacy data from LumiThera's LIGHTSITE III clinical trial in intermediate dry age-related macular degeneration, which could support a future FDA approval filing in the United States.PR NewswireLumiThera, Inc. gibt Abschluss der Akquisition von Diopsys, Inc. bekanntLumiThera Inc., a Seattle-based medical technology company, has completed the acquisition of Diopsys, Inc., a leading provider of visual electrophysiology medical devices. Diopsys becomes a wholly-owned subsidiary of LumiThera, creating a complementary diagnostic and monitoring platform to LumiThera's Valeda Light Delivery System for treating eye diseases. The combined entity will unify Diopsys' established US distribution team with LumiThera's EU distribution network to serve eye care professionals globally.